ArticleAnnals of nuclear medicine2026
Predictive value of
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Response to the comment on the impact of anti-HER2 therapy on the accuracy of 68 Ga-HER2-affibody PET/CT imaging in metastatic breast cancer.Annals of nuclear medicine · 2025Article
- Comment on the impact of anti-HER2 therapy on the accuracy of 68 Ga-HER2-affibody PET/CT imaging in metastatic breast cancer.Annals of nuclear medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDevelopment and validation of a radiomics model based on pretreatment deoxy-2-[fluorine-18]-fluoro-D-glucose positron emission tomography/computed tomography (
methodsA retrospective analysis was performed on 145 patients with ESCC, using pretreatment
resultsMaximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and gender were significantly associated with LNM in ESCC (all P < 0.05). SUVmax was found to be an independent risk factor for predicting LNM in ESCC. In the training and validation cohorts, the areas under the curve (AUC) for SUVmax combined with Radscore were 0.809 (95% CI: 0.723-0.894) and 0.801 (95% CI: 0.661-0.941), respectively, both of which were higher than those for SUVmax and Radscore alone. A nomogram, a comprehensive predictive model based on SUVmax and Radscore, may improve the net clinical benefit for patients.
conclusionThe nomogram, a predictive model developed using
Indexed as
Identifiers
41091337What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.